Kornimate/medical-research-clean huggingface dataset:
use of acthar in rheumatoid arthritis (ra) related flares

Conditions: Rheumatoid Arthritis (RA)

Summary: this is a rheumatoid arthritis (ra) study. the purpose of this research study is to determine in ra flare, whether musculoskeletal ultrasound (msus) inflammatory scores and/or disease activity scores improve with acthar treatment.

participants with active ra flair will be assigned to take on one of two acthar doses, either 40 units per week or 80 units twice a week. both arms will be taking the drug for 4 weeks. each participant will be coming back for visits at 2 weeks, 1 month and 3 months after the initial baseline visit. during these visits the following information will be collected: msus of joints, das28, clinical disease activity index (cdai), routine assessment of patient index data 3 (rapid3) and health assessment questionnaire-disability index (haq-di). participants will also be asked to fill out a questionnaire about their health status. efficacy of acthar to decrease evidence of msus synovitis and disease activity measures will be analyzed using the above mentioned instruments, as well as acthar's ability to prevent the necessity to change patients' ra treatment regimen.

Eligibility criteria:
inclusion criteria: 1. patient must meet 1987 acr criteria 2. age \> 18 years of age 3. baseline das28/erythrocyte sedimentation rate (esr) \>=3.2 4. stable concomitant disease modifying anti-rheumatic drugs (dmards) 5. stable prednisone \<10mg or equivalent 6. power doppler score of \>=10 exclusion criteria: 1. prior treatment with acthar in the past 2mos 2. meet one of the above ra flare requirements 3. subjects who have received live or live attenuated vaccines within 6 weeks prior to the first dose of study drug (or the zoster vaccine)

Keywords: rheumatoid arthritis (ra) musculoskeletal ultrasound (msus)
efficacy and safety of preemptive intravenous dexamethasone in mis-tlif : double blinded, randomized control trial

Conditions: Spinal Stenosis Lumbar; Disc Degeneration; Disc Disease; Fusion of Spine; Surgery

Summary: researchers are considering dexamethasone as preemptive medication before minimally invasive spine fusion surgery to minimize postoperative back pain with minimal side effects, aiming to enhance the effectiveness of surgery and improve patient outcomes.

surgery for spine fusion through a minimally invasive technique called mis-tlif has become increasingly popular nowadays due to various reasons such as lower blood loss and reduced need for blood transfusions, less postoperative back pain, and shorter surgical duration compared to the traditional technique known as tlif. however, even after mis tlif, patients still experience issues such as wound or back pain, which can affect their physical activity and increase the risk of infection. prolonged hospital stays lead to resource wastage. in the enhanced recovery after surgery (eras) program for spine surgery, preoperative medication, including acetaminophen, nsaids, and gabapentinoids, is recommended to alleviate postoperative back pain. however, even after implementing eras, patients undergoing mis tlif still experience pain, suggesting that further pain reduction strategies are needed. the use of dexamethasone as preemptive medication has shown promising results in various surgeries, with minimal side effects and a manageable cost. dexamethasone, administered via injection, has a longer duration of action compared to other steroids, making it suitable for preemptive use. the main objective is to study the effectiveness of using dexamethasone via intravenous injection before minimally invasive spine fusion surgery, known as mis-tlif, in reducing postoperative back pain. the secondary objectives are to compare the rate of morphine usage for pain management after surgery between two groups. to compare the side effects and adverse reactions of the medication, such as nausea and vomiting, surgical site infection rates, and blood sugar levels post-surgery. to compare the fusion rates of the spinal bones. to compare the length of hospital stays after surgery.

Eligibility criteria:
inclusion criteria: * age range: 50-80 years old. * undergoing mis tlif surgery at 1-2 spinal levels. exclusion criteria: * previously undergone spine surgery. * hba1c greater than or equal to 7.5 mg% * allergic to all types of experimental medication. * history of using systemic steroids.
the effect of orthopulse photobiomodulation on the rate of tooth movement during alignment with fixed appliances

Conditions: Malocclusion

Summary: the aim of this study is to determine efficacy of orthopulse photobiomodulation on the rate of tooth movement during alignment for subjects receiving fixed appliance orthodontic treatment.


Eligibility criteria:
inclusion criteria: * presence of permanent dentition * eligible and scheduled for full-mouth, fixed-appliance orthodontic treatment * moderate to severe crowding (lii ≥ 3 mm), with no labio-lingually displaced teeth * class i or class ii malocclusion by ½ cusp or less * non-extraction in both arches * age 11-60 * good oral hygiene * non-smoker; non-use of chewing tobacco exclusion criteria: * subject is currently enrolled in another clinical study * subject decided on invisalign rather than braces * periodontally involved teeth * use of bisphosphonates (osteoporosis drugs) during the study * subject plans to relocate over the treatment period * spaces between anterior teeth * subject has dental implants or an implanted prosthesis * sponsor employees, the investigator and staff, as well as their immediate family members

Keywords: alignment phase photobiomodulation orthodontic treatment malocclusion orthopulse™
evaluation of regional distribution of ventilation during labor with or without epidural analgesia

Conditions: Pregnancy; Atelectasis

Summary: with an efficient epidural analgesia the physiological effects of pain are disabled during labor. pain may cause an increase of minute volume, oxygen consumption and a decrease of paco2 (arterial co2 pressure). the study will evaluate the lung function before and after labor with and without epidural analgesia. with more efficient breathing, the occurence of atelectasis should be reduced; this effect will be investigated in these settings for the first time with the electrical impedance tomography, which is a completely non-invasive measure.

the bedside efficacy of the electrical impedance tomography (eit) in intensive care settings during mechanical ventilation is known. however, no studies demonstrate its utility during epidural analgesia for labor. the purpose of this study is to evaluate lung function and atelectasis in pregnant women with or without epidural analgesia, during labor and after delivery. only adult consenting patients asa i \& asa ii (american society of anaesthesiologists) are included in the study. according to institutional protocols lumbal epidural catheter is inserted and tested at the start of the labor, while patients' parameters are monitored. refusal to epidural analgesia, technical difficulties to insert the epidural catheter or any medical contraindication will result in inclusion of these patients in the control group. measurement with eit is not invasive and harmful neither for the mother nor for the child. it consists of putting a belt around the chest; this belt is linked to a monitor which measures the impedance of the different lung regions. electrical impedance measurements will be done for short periods of maximum 5 min. each as follows: 1. placement before injection of local anesthetics through the epidural catheter in the study goup; in the control subset placement of the belt will be done when an epidural anesthetic would have been considered. 2. 1 hour after placement of the belt 3. 1 hour after delivery these periods will be compared.

Eligibility criteria:
inclusion criteria: * asa i * asa ii exclusion criteria: * caesarian * \< 18 years * expulsions

Keywords: epidural analgesia for labor respiratory function electrical impedance tomography
indications and outcomes of endoscopic ultrasound in tanta

Conditions: Gastric Disease; Intestinal Disease; Pancreatic Diseases; Esophageal Diseases

Summary: the aim is to evaluate the initial experience for the indications and outcomes of eus in tanta university hospital.

detection of main causes for referral to eus in tanta, egypt.

Eligibility criteria:
inclusion criteria: * all cases of gastrointestinal eus exclusion criteria: * missed data
the influence of pressure pain on [11c]diprenorphine binding potentials

Conditions: Healthy Controls

Summary: healthy volunteers aged 21 to 50 are needed for a research study investigating whether pain will alter the binding properties of (\[11c\]diprenorphine), a molecule that can be used during brain imaging. positron emission tomography (pet) and functional magnetic resonance (fmri) imaging will be used in this study.


Eligibility criteria:
inclusion criteria: * healthy male and female adults, 21 to 50 years of age * no contraindications to fmri and pet scanning * within 15% of ideal body mass index (bmi) exclusion criteria: * current significant medical, neurological, or psychiatric illness as assessed by the physician investigators * women who are pregnant or breast feeding, have gone through menopause, and/or have irregular menstrual cycles * claustrophobia * history of head trauma * instability of responses to experimental pain (see study procedure section part ii) * history of asthma * use of psychotropic drugs or hormone treatments (including hormonal birth control) within one year of date of consent * history of smoking * routine exercise in excess of one hour per day and/or three times per week * non-fluent english speaker
retrospective observational study to compare cystic fibrosis patients in two decades before and after 2000

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to describe two cohorts of cystic fibrosis patients treated in 2 different decades in terms of fev1 (forced expiratory volume in one second) maintenance.

the purpose of this study is to describe two cohorts of cystic fibrosis patients treated in terms of fev1 maintenance from the age of 10 to 15 before and after 2000.

Eligibility criteria:
inclusion criteria: * patients with cystic fibrosis diagnosed with neo-natal screening * patients born between 01/01/1979 and 12/31/1984 (cohort 1)and patients born between 01/01/1991 and 12/31/1996 (cohort 2) * patients with at least 2 fev1 yearly measurements from the age of 10 to 15 exclusion criteria: * patients with malignant tumor * patients with meconium ileus * patients with transplantation (pneumectomy or lobectomy) * patients involved in any other clinical trial * patients moved to another clinical center

Keywords: cystic fibrosis pseudomonas aeruginosa
rapid gastric and pancreas cancer staging utilizing peritoneal lavage

Conditions: Gastric Cancer; Pancreatic Cancer

Summary: this study is being done to develop a new method that can rapidly stage patients with gastric and pancreas cancer. staging means finding out what is the extent of the cancer in a patient's body. currently before patients have the surgery to remove their cancer, a surgical exam is done in the operating room to see if their cancer has spread. a thin tube-like instrument with lens and a light is placed into the abdomen. this is done by making small cuts into the body. this exam is called a diagnostic laparoscopy. if cancer spread is not seen, fluid is put into the abdomen and then taken out. this is called "lavage" or washing. the fluid is then looked at in a laboratory. if the fluid contains cancer cells surgery is often delayed. the investigators are testing a new method to put the fluid into the abdomen. it is called percutaneous lavage. percutaneous means "through the skin". a needle is put through the skin into the abdomen. tubing is then placed over the needle so that fluid can be put into the abdomen and then taken out. the fluid is then looked at in a laboratory. the investigators want to see if the two methods are equal because if they are equal, in the future, patients may be able to have this procedure done outside of the operating room.


Eligibility criteria:
inclusion criteria: * men and women 18 years of age and older * informed consent in keeping with the policies of memorial sloan-kettering cancer center * presentation of gastric or pancreatic cancer based on objective findings by either: * ct scan * endoscopy * pathologic examination * candidate for surgical treatment and are scheduled for laparoscopy with peritoneal lavage. exclusion criteria: * under 18 years of age * inability to speak or read english, and an appropriate translator is not identifiable * unable or unwilling to give informed consent * patients with synchronous cancers of other abdominal organs * multiple prior surgical procedures on the abdomen where the surgeon feels that percutaneous lavage may be dangerous.

Keywords: gastric pancreas laparoscopy peritoneal lavage 10-011 gastric and pancreatic cancer
remote ischaemic preconditioning to prevent dialysis induced cardiac injury

Conditions: Hemodialysis; Cardiovascular Diseases

Summary: this study evaluates the use of remote ischaemic preconditioning for the prevention of dialysis induced cardiac injury. the study uses four arms to test different frequencies of application to ascertain which, if any, is most successful at reducing dialysis induced cardiac injury.


Eligibility criteria:
inclusion criteria: 1. patients having haemodialysis treatment at least 3 times per week at a london health sciences centre facility 2. male and female, age≥16 years old. exclusion criteria: 1. not meeting inclusion criteria 2. exposure to haemodialysis for \<90 days prior to recruitment 3. severe heart failure (new york heart association grade iv) 4. cardiac transplant recipients 5. mental incapacity to consent 6. declined to participate 7. taking cyclosporin 8. taking atp-sensitive potassium channel opening or blocking drugs
the effects of acute ketone monoester supplementation on exercise efficiency and the influence of dose and intensity

Conditions: Exercise; Ketosis

Summary: diet can alter blood ketone levels and this in turn may affect exercise capacity. this study will determine if the acute ingestion of a ketone supplement alters cycling exercise efficiency. participants will perform three trials in a randomized order. each trial will involve an incremental exercise protocol on a stationary cycle ergometer to volitional fatigue. participants will ingest either a high or low dose of a ketone supplement or a taste-matched placebo drink prior to exercise. blood samples will be obtained to assess selected metabolic responses. this study will provide information regarding the effect of ketone supplementation on exercise efficiency.

this study will determine if the acute ingestion of a ketone supplement alters cycling exercise efficiency. trained participants with cycling experience will be recruited. participants will perform three trials in a randomized order. each trial will involve a 3-minute warm-up followed by an incremental ramp test. the ramp will initially consist of three, 5-minute stages performed at relative workloads corresponding to 75%, 100%, and 125% of individual ventilatory threshold intensity. this will be followed by a further incremental ramp test to volitional fatigue. participants will ingest either a high or low dose of a ketone supplement or a taste-matched placebo drink prior to exercise using a randomized, double-blind crossover design. diet prior to exercise will be standardized between trials for a given participant. blood samples will be obtained to assess selected metabolic responses. this study will provide information regarding the effect of ketone supplementation on exercise efficiency.

Eligibility criteria:
inclusion criteria: * be habitually consuming ≥50 g/d of carbohydrate (i.e., not following a ketogenic diet). * be engaged in endurance-type exercise \>3h/wk. * have an estimated vo2peak of ≥90% for age and sex as estimated by an online calculator found at www.worldfitnesslevel.org. exclusion criteria: * experiencing a condition that might preclude safe participation in physical activity and exercise, as determined by answering "yes" to any question on page 1 of the canadian society for exercise physiology get active questionnaire.

Keywords: efficiency
intraocular pressure (iop) patterns in fast versus slow visual field (vf) progression patients

Conditions: Primary Open-angle Glaucoma (POAG) Patient

Summary: the purpose of this study is to investigate how the intraocular pressure (iop) varies in time and if the iop variations are associated with the worsening of glaucoma. iop patterns will be recorded continuously over 24 hours with sensimed triggerfish® (tf) a portable investigational device using a contact lens sensor. after completing the triggerfish lens placement and removal; the patient will complete a formal polysomnography.


Eligibility criteria:
inclusion criteria: * age between 40 and 89 years old * diagnosis of treated poag (including normal tension glaucoma (ntg)) * all iop measurements during the vf period (to be described further) equal or lower than 18 mmhg and/or on average equal or lower than 16 mmhg in the same period * documented glaucomatous vf damage at baseline, characterized by glaucoma hemifield test result outside normal limits on at least 2 consecutive vf tests or the presence of at least 3 contiguous test points within the same hemifield on the pattern deviation plot at p\<0.01, with at least 1 point at p \< 0.005 * at least 8 visual field tests carried out within at least 2 years, all with fixation losses and false positive/negative results equal or less than 33% * for fast progressing eyes, 1) pointwise progression defined as two or more adjacent vf test locations in the same hemifield that show a threshold sensitivity rate of change more negative than -1.0 db/year with p\<0.01 or 2) a global rate of vf change based on mean deviation (md) more negative than -1.0 db/year * for slowly or minimally progressing eyes a vf md rate of change more positive than -0.5 db/year with no significant pointwise progression as described above * not more than 6 diopters spherical equivalent on the study eye * have given written informed consent, prior to any investigational procedures exclusion criteria: * baseline vf md more negative than -15 db. the rationale here is that in severely damaged visual fields, one may not be able to detect and measure rates of progression due to a 'floor effect' * corneal or conjunctival abnormality precluding contact lens adaptation * severe dry eye syndrome or other ocular disease * patients with angle closure glaucoma, traumatic glaucoma or uveitic glaucoma * patients with previous intraocular surgery in the enrolled eye, including cataract surgery * patients with allergy to corneal anesthetic * patients with contraindications for silicone contact lens wear * patients not able to understand the character and individual consequences of the investigation * participation in unrelated clinical research within the last 4 weeks
a study to assess the safety, tolerability, and efficacy of rocatinlimab in adolescent participants with moderate-to-severe atopic dermatitis (ad)

Conditions: Atopic Dermatitis

Summary: the primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe ad.


Eligibility criteria:
inclusion criteria: * age ≥ 12 to \< 18 years at day 1. * participant has a diagnosis of ad (according to american academy of dermatology consensus criteria \[eichenfield, 2014\]) that has been present for at least 12 months before signing of informed consent * prior to informed consent, history of inadequate response to topical corticosteroids (tcs) of medium to higher potency (with or without topical calcineurin inhibitors \[tci\] as appropriate) or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks) * eczema area and severity index (easi) score ≥ 12 * viga-ad score ≥ 3 * ≥ 10% bsa of ad involvement at day 1 pre-enrollment exclusion criteria: * treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 * treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to day 1: * systemic corticosteroids * systemic immunosuppressants * phototherapy * oral or topical janus kinase inhibitors * treatment with any of the following agents within 1 week before day 1 pre-enrollment: * topical pde4 inhibitors * other topical immunosuppressive agents (not including tcs/tci) * combination topical agents containing a high- or super-high potency corticosteroid

Keywords: atopic dermatitis rocatinlimab amg 451 khk4083
role of proteasomes in a dermatological autoimmune disease: bullous pemphigoid

Conditions: Pemphigoid, Bullous; Pemphigus; Lupus Erythematosus, Cutaneous

Summary: the primary objective of this study is to describe and compare plasmatic anti-proteasome auto-antibody concentrations among three distinct groups: (1) patients suffering from bullous pemphigoide; (2) patients suffering from other dermatological auto-immune diseases; (3) an elderly control group.

the secondary objectives of this study are: to compare the following parameters between the 3 groups: * plasmatic proteasome concentrations * plasmatic proteasome proteolytic activity to explore the potential relationships between: * plasmatic proteasome concentrations * plasmatic proteasome proteolytic activity * plasmatic anti-proteasome auto-antibody concentrations * measures of disease severity for dermatological auto-immune diseases to characterize plasmatic anti-proteasome auto-antibodies in patients suffering from bullous pemphigoide and other dermatological auto-immune diseases (other bullous auto immune diseases: pemphigus, cutaneous lupus, ...). to characterize the expression and the activity of proteasomes in skin samples, in plasma and in circulating mononuclear cells in patients with bullous pemphigoide.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is not taking systemic treatment * the patient has not been treated with topical steroids for more than 15 days. for the bullous pemphigoid group: * clinical signs: erythematous-based lesions, especially on flexion areas of the arms and legs, not afflicting mucous membranes, and without atrophic scaring * histology: without epidermal acantholysis for the pemphigus group: * patient with pemphigus for the lupus group: * systemic lupus patients: presence of the 4 diagnostic criteria for systemic lupus erythematosus as defined by the american college of rheumatology (amended 1997) * or characteristics of subacute cutaneous lupus: clinical, histological and immunological (anti-ssa) * or clinical and histological characteristics of chronic lupus for the control group: * hospitalized patients with no history of auto-immune, inflammatory or evolving neoplastic disease exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding for patients with bullous pemphigoid, pemphigus or lupus: * the patient is taking systemic treatment * the patient has been taking topical steroids for more than 15 days. for the controls: * autoimmune disease * inflammatory disease * evolving neoplastic disease * surgery during the last 6 months

Keywords: proteasomes proteasome concentration disease activity proteolytic activity autoantibodies proteasome autoantibody